Mr Mrs Miss Ms Dr Other

Dr
Nienke
Lubben

Partner & Patent Attorney

York Office The Hague Office

Chemistry

Telephone. +44(0) 1904 732 120
Mobile. +44(0) 777 265 2294
Email. nlubben@hgf.com
UPC Representative
Our team of specialist European patent litigators, oppositions specialists and patent attorneys bring together an extensive depth of legal and technical knowledge and are qualified to represent you in the UPC.
Vcard

Experience

Nienke is a European and UK Patent Attorney. Her client base includes several universities, start-ups, independent research institutes and small to medium enterprises. She advises on IP portfolio management and strategy, drafting, patent prosecution, freedom to operate and due diligence relating to potential asset licencing, acquisition or investment. Her extensive experience in drafting and analysing the value of third party patents and patent applications has given her a good understanding of how to prepare patent applications that are attractive to potential investors and licensees. In terms of technologies, Nienke specialises in the field of cell and gene therapy, with particular experience in TCR and CAR-T cell therapies. She has experience in a diverse range of technical subject matter including antibody and peptide therapeutics, viral vector production, biomarkers and diagnostic methods. She has a PhD in cell biology and immunology.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Chartered (UK)
Europe

BSC

Biological Sciences (genetics)

PHD

Cell Biology and Immunology

Recognition

MIP IP Rising Star 2019/20

MIP IP Rising Star 2018/19

Publications

Managing Intellectual Property firm rankings - IP Stars 2024

View publication online

MIP IP Rising Stars 2019/20

View publication online

Related News

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

Regulatory Exclusivity for
Medicinal Products in Europe

Video overview: New Medical Products 8 years of data exclusivity, followed by 2 years of market exclusivity. +1 year market exclusivity possible for a new indication showing significant clinical benefit. No exclusivity granted for new formulations or routes of …

Read article

Added Matter - Part 2

Video overview: Pre- and Post-Grant Amendments are governed by Articles 123(2) & 123(3) EPC respectively Before grant, amendments can broaden the claim scope as long as the resulting claim is …

Read article

Added Matter - Part 1

Video overview: What is Added Matter? Added matter occurs when an amendment introduces content that goes beyond what was originally disclosed in the application as filed (Article 123(2) EPC). EPO …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us